Hantz Financial Services’s Pacific Biosciences PACB Stock Holding History

Hantz Financial Services’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$0	Hold	4	–	–	﹤0.01%	2571
2025 Q4	$0	Hold	4	–	–	﹤0.01%	2504
2025 Q3	$0	Hold	4	–	–	﹤0.01%	2420
2025 Q2	$0	Hold	4	–	–	﹤0.01%	2270
2025 Q1	$0	Hold	4	–	–	﹤0.01%	1902
2024 Q4	$0	Hold	4	–	–	﹤0.01%	1184
2024 Q3	$0	Hold	4	–	–	﹤0.01%	1157
2024 Q2	$0	Hold	4	–	–	﹤0.01%	1213
2024 Q1	$0	Hold	4	–	–	﹤0.01%	1275
2023 Q4	$0	Hold	4	–	–	﹤0.01%	1204
2023 Q3	$0	Hold	4	–	–	﹤0.01%	1173
2023 Q2	$0	Hold	4	–	–	﹤0.01%	1154
2023 Q1	$0	Hold	4	–	–	﹤0.01%	1180
2022 Q4	$0	Hold	4	–	–	﹤0.01%	1140
2022 Q3	$0	Hold	4	–	–	﹤0.01%	1128
2022 Q2	$0	Hold	4	–	–	﹤0.01%	1099
2022 Q1	$0	Hold	4	–	–	﹤0.01%	1105
2021 Q4	$0	Buy	+4	New	+$97	﹤0.01%	896

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hantz Financial Services's PACB Position: Q1 2026 in Review

Hantz Financial Services held its Pacific Biosciences (PACB) position steady in Q1 2026 at 4 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2571.

Hantz Financial Services first reported a position in PACB in Q4 2021 and has held it in 18 quarters since. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Hantz Financial Services held 4 shares of Pacific Biosciences worth $0 as of Q1 2026.
Hantz Financial Services left its Pacific Biosciences share count unchanged in Q1 2026.
Pacific Biosciences made up ﹤0.01% of Hantz Financial Services's portfolio in Q1 2026, its #2571 holding.
Hantz Financial Services first reported a position in Pacific Biosciences in Q4 2021 and has held it in 18 quarters since.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.